Intensity Therapeutics Earns Platinum Pinnacle Award for INT230-6 Intratumoral Platform
Intensity Therapeutics received the Platinum Award in the Innovator in Biotech Solutions category at the 2026 Pinnacle Awards for its intratumoral injection platform and lead candidate INT230-6. INT230-6 combines cisplatin, vinblastine sulfate, and a SHAO enhancer to disperse cytotoxic drugs throughout tumors.
1. Award Recognition
Intensity Therapeutics won the Platinum Award in the Innovator in Biotech Solutions category at the 2026 Pinnacle Awards. This accolade highlights the company's intratumoral injection platform and its lead candidate INT230-6.
2. Drug Technology
INT230-6 comprises cisplatin and vinblastine sulfate non-covalently conjugated with a SHAO enhancer, enabling broad dispersion of potent cytotoxics within tumor tissues and improved immune system recognition.
3. Clinical Development Progress
INT230-6 is in a Phase 3 soft tissue sarcoma trial (INVINCIBLE-3) with overall survival as the primary endpoint and a Phase 2/3 triple-negative breast cancer study (INVINCIBLE-4) evaluating pathological complete response rates alongside standard immunochemotherapy.